Exchange: NASDAQ·Updated 01:11 PM EDT
IMTX logo

IMTX Immatics N.V

$9.41
$0.05
(0.53%)
Today
Reported EarningsAug 18
Mkt Cap$1.42B
Vol109,468.00

About IMTX

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.
35

Bearish Sentiment

How do you feel about IMTX?

Advertisement|Remove ads.